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etter to the Editor
ssessment  of  the treatment  of chronic  hepatitis  C virus
nfection: a case  series from a  hospital  in  the  Brazilian
rmazon region
ear Editor,
ccording to the World Health Organization, more  than 170
illion  people worldwide are infected with HCV, correspond-
ng  to 3% of the world population, with an important impact
n  global public health.1 More  than 20 years have elapsed
ince  the discovery of the putative virus. The efﬁcacy of
hronic  hepatitis C treatment has improved over the past
ecade,  but treatment with interferon (IFN) is unable to eradi-
ate  HCV in chronically infected patients.2 In treatment-naive
atients who  are infected with HCV genotype 1 and present a
igh viral load, a sustained virological response (SVR) rate of
0%  is obtained with conventional IFN and about 50% with
he  combination of pegylated IFN (PEG-IFN) and ribavirin.3
romising results have been reported for patients infected
ith  HCV genotype 1 when a protease inhibitor either telapre-
ir  or boceprevir is added to PEG-IFN plus ribavirin, with an
ncrease  in SVR rates from 50% (PEG-IFN + ribavirin) to around
0%  (PEG-IFN + ribavirin + protease inhibitor). In Brazil some
tudies  evaluating the efﬁcacy of the treatment for chronic
epatitis C have been published, such as the study conducted
y  Azevedo et al., who ﬁrst demonstrated a SVR rate of 32.6%
n  the state of Mato Grosso, lower than rates found in the
outh  and Southeast regions.4 I would like to share the prelim-
nary  results of a larger study of the treatment of the hepatitis
 virus infection in which we  are investigating the role of
nterleukin  28B and ancestrality as predictive factors of SVR.
he  treatment of hepatitis C virus (HCV) infection is provided
ree-of-charge by the national public health system (SUS) in
elém do Pará, northern Brazil, where conventional interferon
r  pegylated interferon combined with ribavirin was used in
he study period. A total of 251 patients seen between 2002
nd  2011 at the liver outpatient service of the of Fundac¸ão
anta Casa de Misericórdia do Pará (FSCMPA) Hospital, Belém,
ará,  Brazil, were  included in the study. Some patients were
xcluded  because of incomplete information in the medical
ecords.  Data entry and statistical analysis of research data
ere  carried on in EPI INFO 6.0 and 5.0 BioEstat softwares. Out
f  the 251 patients, 86 (34%) received conventional IFN and 165
66%) received PEG-IFN, both combined with ribavirin. Table
11 summarizes the patient variables of the 251 HCV-infected
patients treated with conventional IFN or PEG-IFN plus riba-
virin.  Among patients receiving conventional IFN, 52/86 (60%)
had  mild ﬁbrosis (F1 and F2), 56/86 (65%) were  infected with
HCV  non-genotype 1, and 41/86 (48%) achieved SVR. Patients
infected  with genotype 1 achieved 30% SVR compared to 58%
of  patients with non-genotype 1 (p = 0.01). Seventy-nine (48%)
of  the 165 patients receiving PEG-IFN had ﬁbrosis stage F2.
HCV  genotype 1 was  the most frequent (84.24%) and 88/165
(53%)  patients achieved SVR whereas 52% (72/139) of patients
infected  with non-genotype 1 in this group achieved SVR. The
SVR  rate according to ﬁbrosis stage, irrespective of HCV geno-
type,  was  53.7% in patients with stage F2 and 8% in patients
with  stage F4 (p = 0.0068). The main objective of hepatitis C
treatment  is to eradicate the virus and to prevent cirrhosis
and  its complications, as well as hepatocellular carcinoma.
The  overall objective is not met  in case of failure to eradicate
the  virus. In the present study, half of the patients chronically
infected with HCV who were treated with conventional IFN
and  ribavirin did not achieve SVR. Analysis according to HCV
genotype  showed that only 31% of patients with genotype 1
achieved SVR. A study analyzing 87 patients with chronic hep-
atitis  C seen at the Federal University of Paraná, who  received
conventional IFN plus ribavirin provided by the Ministry of
Health,  yielded an overall SVR of about 30%. This rate is sim-
ilar  to those reported in the international literature, although
recent  studies have achieved rates close to 40%.5 The introduc-
tion  of protease inhibitors is expected to enhance SVR rates in
Belem, Para.
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